Clinical Trials: Phase I/II Study Using a Non-Myeloablative Lymphocyte Depleting Regimen of Chemotherapy Followed by Infusion of Allogeneic Tumor-Reactive Lymphocyte Cell Line DMF5 in Metastatic Melanoma
Sponsor and CollaboratorsNational Cancer Institute (NCI)
Contact
Recruitment Center - SB
866-820-4505
ncisbirc@mail.nih.gov
Principal Investigator
None indicated
ClinicalTrials.gov Identifier
NCT00924001
